[{"NetIncomeLoss_1_Q1_USD":-14185000.0,"OperatingLeaseLiability_0_Q1_USD":306000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"GeneralAndAdministrativeExpense_1_Q1_USD":4359000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":40055435.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q1_USD":-0.35,"CommitmentsAndContingencies_0_Q1_USD":null,"FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_0_Q1_USD":64000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-7000.0,"InterestIncomeExpenseNonoperatingNet_1_Q1_USD":-3000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_1_Q1_USD":0.0,"AssetsCurrent_0_Q1_USD":432327000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_0_Q1_USD":144000.0,"FinanceLeaseLiabilityNoncurrent_0_Q1_USD":131000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":4352067.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":1024000.0,"FinanceLeaseLiabilityUndiscountedExcessAmount_0_Q1_USD":6000.0,"FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":72000.0,"CommonStockSharesIssued_0_Q1_shares":40208569.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_1_Q1_USD":292000.0,"Assets_0_Q1_USD":432910000.0,"IncreaseDecreaseInOtherAccruedLiabilities_1_Q1_USD":585000.0,"Liabilities_0_Q1_USD":14426000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":9849000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":311000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":26000.0,"CommonStockValue_0_Q1_USD":40000.0,"LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_0_Q1_USD":62000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":5000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":778000.0,"FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_0_Q1_USD":96000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1_Q1_USD":0.0,"FinanceLeaseLiabilityPaymentsDue_0_Q1_USD":232000.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1_Q1_USD":0.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q1_USD":6779000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-14185000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":7346000.0,"OtherAssetsNoncurrent_0_Q1_USD":536000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":429855000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":166000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":551151000.0,"FinanceLeaseLiability_0_Q1_USD":226000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":105000.0,"ShareBasedCompensation_1_Q1_USD":1800000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q1_shares":9720932.0,"CommonStockSharesOutstanding_0_Q1_shares":40208569.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q1_USD":30000.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q1_pure":0.0187,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-14185000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":1800000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-5135000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":40055435.0,"LiabilitiesCurrent_0_Q1_USD":14129000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1_Q1_USD":-4364000.0,"AccountsPayableCurrent_0_Q1_USD":7350000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":429855000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":2472000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":778000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":103000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q1_pure":0.0169,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_1_Q1_USD":0.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":47000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-132707000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":300000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":7000.0,"FinanceLeaseLiabilityCurrent_0_Q1_USD":95000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q1_USD":5000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":453000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"CommonStockSharesAuthorized_0_Q1_shares":1000000000.0,"OperatingIncomeLoss_1_Q1_USD":-14208000.0,"PreferredStockValue_0_Q1_USD":null,"LiabilitiesAndStockholdersEquity_0_Q1_USD":432910000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":1802000.0,"PreferredStockSharesAuthorized_0_Q1_shares":100000000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":1800000.0,"FinanceLeaseRightOfUseAsset_0_Q1_USD":200000.0,"PropertyPlantAndEquipmentGross_0_Q1_USD":77000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":140000.0,"OperatingExpenses_1_Q1_USD":14208000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.35,"ProfitLoss_1_Q1_USD":-14185000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":297000.0,"StockholdersEquity_0_Q1_USD":418484000.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":307000.0,"Ticker":"ALXO","CIK":"1810182","name":"ALX ONCOLOGY HOLDINGS INC","OfficialName":"ALX Oncology Holdings Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"632216571.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210517"}]